
Krystal Biotech Stock Soars After FDA Label Expansion
Krystal Biotech's stock experienced a significant surge after the FDA expanded the label for its product VYJUVEK. This development is anticipated to enhance market potential and has led TD Cowen to maintain a Buy rating, reflecting strong investor confidence in the company's growth prospects.

Krystal Biotech Stock Soars After FDA Label Expansion
Krystal Biotech's stock experienced a significant surge after the FDA expanded the label for its product VYJUVEK. This development is anticipated to enhance market potential and has led TD Cowen to maintain a Buy rating, reflecting strong investor confidence in the company's growth prospects.
Why World Pulse Now
Global Coverage
All major sources, one page
Emotional Lens
Feel the mood behind headlines
Trending Stories
Know what’s trending, globally
Read Less, Know More
Get summaries. Save time
Multi-Language
Switch languages to read your way
Save for Later
Your stories, stored for later
Live Stats
Our system has analyzed 7,775 articles worldwide
~323 per hour
564 trending stories shaping headlines
From breaking news to viral moments
Monitoring 200 trusted sources
Major outlets & specialized publications
Latest update an hour ago
Always fresh